ATE384075T1 - Markierte glutamin- und lysinanaloge - Google Patents

Markierte glutamin- und lysinanaloge

Info

Publication number
ATE384075T1
ATE384075T1 AT99922325T AT99922325T ATE384075T1 AT E384075 T1 ATE384075 T1 AT E384075T1 AT 99922325 T AT99922325 T AT 99922325T AT 99922325 T AT99922325 T AT 99922325T AT E384075 T1 ATE384075 T1 AT E384075T1
Authority
AT
Austria
Prior art keywords
glutamine
lysine analogues
lysine
labeled glutamine
peptidases
Prior art date
Application number
AT99922325T
Other languages
English (en)
Inventor
Anthony Eamon Storey
Marivi Mendizabal
Susan Champion
Alex Gibson
Benedicte Guilbert
Ian Andrew Wilson
Peter Knox
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Application granted granted Critical
Publication of ATE384075T1 publication Critical patent/ATE384075T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99922325T 1998-05-15 1999-05-14 Markierte glutamin- und lysinanaloge ATE384075T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98303872 1998-05-15

Publications (1)

Publication Number Publication Date
ATE384075T1 true ATE384075T1 (de) 2008-02-15

Family

ID=8234827

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922325T ATE384075T1 (de) 1998-05-15 1999-05-14 Markierte glutamin- und lysinanaloge

Country Status (17)

Country Link
US (2) US7049289B1 (de)
EP (1) EP1077998B1 (de)
JP (2) JP4199420B2 (de)
KR (1) KR100660509B1 (de)
CN (2) CN1309661A (de)
AT (1) ATE384075T1 (de)
AU (1) AU762736B2 (de)
BR (1) BR9910468A (de)
CA (1) CA2332277A1 (de)
DE (1) DE69937996T2 (de)
ES (1) ES2299245T3 (de)
HU (1) HUP0102154A3 (de)
IL (1) IL139385A (de)
NO (1) NO20005751L (de)
RU (1) RU2205186C2 (de)
WO (1) WO1999060018A1 (de)
ZA (1) ZA200006313B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054088A2 (en) 2001-01-05 2002-07-11 Duke University Contrast enhancement agent for magnetic resonance imaging
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
BRPI0210886B8 (pt) * 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
GB0224799D0 (en) * 2002-10-25 2002-12-04 Amersham Plc Improved complex compositions
WO2004106939A2 (en) * 2003-06-03 2004-12-09 Paul Scherrer Institut Method for the linkage of bifunctional chelating agents and (radioactive) transition metal complexes to proteins and peptides
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
RU2428415C2 (ru) 2005-11-29 2011-09-10 Нихон Меди-Физикс Ко., Лтд. Соединение-предшественник органического соединения, меченного радиоактивным галогеном
WO2008060368A2 (en) * 2006-10-02 2008-05-22 Duke University Transglutaminase-binding peptides and methods of use
US20130195756A1 (en) 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
US10610608B2 (en) 2013-08-01 2020-04-07 Rochester Institute Of Technology Modular imaging agents containing amino acids and peptides
GB201610176D0 (en) * 2016-06-10 2016-07-27 Edinburgh Molecular Imaging Ltd Imaging agents and methods of use
JP7075937B2 (ja) * 2016-11-09 2022-05-26 キアゲン サイエンシーズ， エルエルシー Ｓｅｑｕｅｎｃｉｎｇ－Ｂｙ－Ｓｙｎｔｈｅｓｉｓ法におけるイメージング試薬としての光防護性混合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4041023A (en) * 1976-04-14 1977-08-09 Hoffmann-La Roche Inc. Labelled peptides
JPS59186947A (ja) * 1983-03-09 1984-10-23 Kowa Co 新規ペプチド
AU2258788A (en) * 1987-07-07 1989-01-30 Cytrx Biopool Ltd. Fibrin-binding compound and method
US5270030A (en) * 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
CA2127284C (en) * 1992-01-03 2002-02-05 Buck A. Rhodes Protein- and peptide-metal ion pharmaceutical applications
US5608110A (en) * 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
DE69830057T2 (de) * 1997-01-21 2006-06-29 Ge Healthcare Ltd., Little Chalfont MARKIERTE FAKTOR XIIIa SUBSTRATE

Also Published As

Publication number Publication date
KR100660509B1 (ko) 2006-12-22
CN1309661A (zh) 2001-08-22
KR20010043608A (ko) 2001-05-25
NO20005751L (no) 2001-01-08
US7049289B1 (en) 2006-05-23
HUP0102154A3 (en) 2009-01-28
DE69937996D1 (de) 2008-03-06
ZA200006313B (en) 2002-07-17
JP4199420B2 (ja) 2008-12-17
IL139385A (en) 2005-09-25
DE69937996T2 (de) 2009-01-02
AU3942899A (en) 1999-12-06
EP1077998B1 (de) 2008-01-16
CN101407543A (zh) 2009-04-15
WO1999060018A1 (en) 1999-11-25
IL139385A0 (en) 2001-11-25
AU762736B2 (en) 2003-07-03
BR9910468A (pt) 2001-01-09
CA2332277A1 (en) 1999-11-25
JP2006137751A (ja) 2006-06-01
HUP0102154A2 (hu) 2001-09-28
EP1077998A1 (de) 2001-02-28
NO20005751D0 (no) 2000-11-14
ES2299245T3 (es) 2008-05-16
US20060292075A1 (en) 2006-12-28
RU2205186C2 (ru) 2003-05-27
JP2002515510A (ja) 2002-05-28

Similar Documents

Publication Publication Date Title
ATE384075T1 (de) Markierte glutamin- und lysinanaloge
SE8502573D0 (sv) Fluorescent lanthanide chelates useful as labels of physiologically active materials
SG54138A1 (en) Dual action inhibitors
DE69637957D1 (de) Zusammensetzung für düngemitteladditivconzentrat
DE69827152D1 (de) Chemilumineszierende zusammensetzungen und entsprechende verfahren
DE69431209D1 (de) Transdermale prostaglandin-zusammensetzung
ES2196630T3 (es) Isotiazolcarboxiamidas y su empleo para la proteccion de las plantas.
BG103995A (en) Reverse hydroxamate inhibitors of matrix metalloprreverse hydroxamate inhibitors of matrix metallprooteinases teinases
FI941832A7 (fi) Menetelmiä NMR:llä havaittavien ksenobioottisten yhdisteiden in vivo määrittämiseksi
FI921279A7 (fi) Amino-b-lyaasientsyymin inhibiittorit deodorantteina
BR9908412A (pt) Composição enzimática estabilizada e método para sua preparação
ES2093819T3 (es) Procedimiento y composicion para determinar la susceptibilidad antimicrobiana de la mayoria de los organismos gram positivos clinicamente significativos.
DE69809944D1 (de) Fettsäuren als eine nährungsergänzung
GB9621814D0 (en) Metalloproteinase inhibitors
BG100248A (bg) Инхибитори на скваленсинтетаза
PT1211250E (pt) Derivados de taxano em c10 e composicoes farmaceuticas
DE60014960D1 (de) Alizarin-derivate als neue chromogene substrate
BR0114884A (pt) Compostos calcilìticos
DE60102218D1 (de) Biotin-peg-substrat für einen lipase-assay
ES2154043T3 (es) Material de obturacion y adhesivo de poliuretano de dos componentes.
NZ510584A (en) Methods and compositions for inhibiting neoplastic cell growth
IT1264084B1 (it) Peptide ad attivita' di substrato e/o inibitore dell'enzima transglutaminasi e suo uso in diagnosi e terapia.
BR9711626A (pt) "composições detergentes compreendendo atividade celulolìtica controlada por anticorpo"
ATE288945T1 (de) Strassenmarkierungsmaterial
UA23145A (uk) Спосіб визhачеhhя активhості бромелаїhу

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties